Dr Aoife Brennan
Dr. Aoife Brennan, M.B. Ch.B., is President and CEO of Synlogic Inc. (Nasdaq: SYBX), a clinical stage bio-technology company bringing the transformative potential of synthetic biology to medicine. She joined Synlogic as Chief Medical Officer in 2016 and was promoted to CEO in October 2018. Prior to joining Synlogic, Aoife served as Vice President and Head of the Rare Disease Innovation Unit at Biogen where her responsibilities included the global marketing approvals of ALPROLIXTM, ELOCTATETM and SPINRAZATM as well as the advancement of several early-phase programs. She served as a Director of Ra Pharmaceuticals from Sept 2018 through their acquisition in April 2020 and currently serves as a Director of Fibrogen and Cerevance. Dr Brennan is originally from Kilkenny and holds a medical degree from Trinity College Dublin, Ireland. She met her husband on her first day of work as a house officer at the Mater Hospital and subsequently completed fellowship training in general internal medicine and endocrinology. She is a graduate of the Harvard Medical School Scholars in Clinical Science Program. Aoife is an advocate for early childhood education, a member of the MA Business Coalition for ECE and a member of the Board of Advisors of Lifescience Cares.